Drug Profile
Pegacaristim
Alternative Names: KRN 9000; Megakaryocyte growth and development factor; MGDF; PEG thrombopoietin - Kirin-Amgen; PEG-MGDF; PEG-rHuMGDF; PEG-rMGDF; Pegylated megakaryocyte growth and development factor; Pegylated recombinant megakaryocyte growth and development factor; Polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor; Thrombopoietin - Kirin-AmgenLatest Information Update: 29 Feb 2008
Price :
$50
*
At a glance
- Originator Amgen; Kirin Brewery; ZymoGenetics
- Developer Amgen; Kirin Holdings Company; ZymoGenetics
- Class Antineoplastics; Growth factors
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chemotherapy-induced damage; Thrombocytopenia
Most Recent Events
- 29 Feb 2008 Discontinued - Phase-II for Thrombocytopenia (Chemotherapy-induced) in Japan (unspecified route)
- 13 Jan 2005 Discontinued - Clinical-Phase-Unknown for Thrombocytopenia (Chemotherapy-induced) in Europe (SC)
- 13 Jan 2005 No development reported - Phase-II for Thrombocytopenia (Chemotherapy-induced) in Japan (unspecified route)